OPKO Health (OPK) Q4 2025 earnings review
Revenue Shrinks Post-Divestiture, But ModeX Platform Secures Major Validation
OPKO's Q4 results highlight a company in deep transition. Consolidated revenue declined 19% YoY to $148.5 million, heavily impacted by the sale of BioReference oncology assets. Operating losses widened to $38.3 million as the remaining diagnostics business failed to meet management's previously touted Q4 breakeven targets. However, the pharmaceutical pipeline delivered a massive win: a collaboration with Regeneron for the ModeX platform that brought in a $7.0M upfront payment and carries a potential value exceeding $1 billion. FY26 guidance projects further revenue deceleration to $530-$560 million as OPKO pivots toward becoming a pure-play R&D organization, supported by $369 million in cash.
🐂 Bull Case
The Regeneron collaboration provides significant non-dilutive capital and major third-party validation for OPKO's multispecific antibody technology. With Merck already advancing the EBV vaccine, the ModeX pipeline is heavily de-risked.
Following asset sales and debt restructuring throughout 2025, OPKO ended the year with $369.1 million in cash and equivalents. This provides a robust runway to fund its aggressive 2026 clinical pipeline without immediate threat of shareholder dilution.
🐻 Bear Case
Management previously guided for the remaining BioReference diagnostics business to reach breakeven by late 2025. Instead, Q4 delivered an $18.3 million segment operating loss, raising questions about the unit's viability.
Partner-driven revenues remain highly lumpy. While Pfizer NGENLA profit share hit a high of $12.5M in Q4, Q1 2026 guidance calls for a severe drop to $5-$6M, and BARDA contract revenue is forecasted to decline materially in FY26.
⚖️ Verdict: ⚪
Neutral. The BioReference segment continues to bleed cash and missed critical profitability milestones. However, the transformative Regeneron deal and robust cash position provide a strong foundation for the underlying ModeX R&D thesis.
Key Themes
Diagnostics Breakeven Target Missed
Management's narrative throughout 2024 and early 2025 suggested the remaining BioReference operations would achieve profitability by Q4 2025 following aggressive cost cuts and the Labcorp asset sale. That trend is Reversing: Q4 Diagnostics operating loss came in at $18.3M. Even after backing out $5.8M in non-recurring transition adjustments, the segment is still deeply in the red at -$12.5M, breaking trust in the near-term cash-flow narrative.
Regeneron Deal Validates ModeX Platform
A major growth Driver emerged with the newly announced research collaboration with Regeneron. The deal applies ModeX's MSTAR platform to Regeneron's proprietary binders. OPKO recognized a $7.0M upfront payment in Q4, and the agreement carries potential milestone payments exceeding $200M per program (overall potential >$1 billion), plus low double-digit royalties. This validates the science and shifts clinical funding burdens to a well-capitalized partner.
NGENLA Profit Share Remains Highly Volatile
Gross profit share from Pfizer for NGENLA is Reversing sharply in early 2026 guidance. Revenues accelerated nicely through FY25, peaking at $12.5M in Q4 (up from $9.6M a year ago). However, Q1 2026 guidance models a severe drop to $5-$6M. This mimics an unexplained Q1 slump seen in 2025 ($4.5M) and complicates cash flow modeling, though FY26 full-year guidance of $34-$37M implies it will recover in later quarters.
4Kscore Test Driving Diagnostics Resilience
While the broader lab business struggles, the 4Kscore test remains a Stable growth Driver. Revenue grew 16% YoY to $7.0M in Q4 2025, benefiting from increased demand and higher average reimbursement. The recent FDA label expansion, which removed the digital rectal exam requirement, continues to successfully unlock the primary care total addressable market.
Rapidly Advancing Broad Clinical Pipeline
OPKO's pipeline is Accelerating into human trials. The MDX2003 trispecific for leukemia/lymphoma was approved for Phase 1 in Australia (starting H1 2026). The MDX2001 tetraspecific advanced to the fifth dose level in Phase 1 with expansion cohorts slated for H1 2026. Furthermore, the Merck-partnered Phase 1 Epstein-Barr virus vaccine trial successfully completed dosing in over 200 healthy adults in Q4, clearing the path for dose and adjuvant selection.
Other KPIs
OPKO actively reduced its share count, buying back $13.5M of stock in Q4 alone. Since the program's authorization in July 2024, the company has deployed $87.3M, leaving $112.7M authorized and available. This showcases management's conviction in the undervaluation of the R&D assets.
Stable YoY compared to $9.1 million in Q4 2024. Despite earlier challenges cited in 2025 regarding the Inflation Reduction Act's impact on volumes, net pricing adjustments have allowed the product to maintain a consistent revenue floor.
Guidance
Decelerating from $606.9 million in FY25. This top-line contraction primarily reflects the absence of BioReference oncology testing revenues (sold to Labcorp in late 2025), alongside an expected drop in BARDA contract milestones.
Accelerating slightly compared to the $31.9 million achieved in FY25. This indicates management expects continued, albeit gradual, global market conversion to long-acting growth hormones, despite guiding for a very weak Q1 26 ($5-$6M).
Decelerating from $28.5 million in FY25. This reduction in non-dilutive funding indicates that earlier phases of pandemic-related development grants are sunsetting, shifting more R&D burden onto OPKO or other partners.
Decelerating from $186.8 million in Q4 2025. R&D spending is guided to remain Stable at $30-$32 million (vs $32.8M in Q4), showing that cost reductions are coming entirely from the streamlined diagnostics cost of goods sold, rather than cuts to the innovation engine.
Key Questions
Diagnostics Cash Burn Strategy
With the Q4 diagnostics operating loss at $18.3M, missing previous breakeven guidance, what structural changes remain to stop the cash bleed? Is further divestiture or total closure of underperforming lab segments on the table?
NGENLA Q1 Seasonality
NGENLA profit share jumped to $12.5M in Q4 but is guided to plummet to $5-$6M in Q1. Is this extreme lumpiness a permanent structural/seasonal feature of the Pfizer agreement, or related to specific inventory destocking?
Regeneron Collaboration Timelines
How many active programs are currently being funded under the new Regeneron collaboration, and what is the expected timeline for the first preclinical or clinical milestone payment?
BARDA Funding Outlook
FY26 guidance shows a material step-down in BARDA revenue to $18-$22M. Does this represent a permanent tapering of government support for the antiviral platforms, and how does this alter out-of-pocket R&D projections for FY27?